A Multi-center, Phase II Study to Evaluate Safety and Efficacy of Adjuvant Chemotherapy With Tegafur Gimeracil Oteracil Potassium Capsule Plus Oxaliplatin and Camrelizumab for Stage III Gastric Cancer (FOCUS-02)
Latest Information Update: 25 Sep 2024
At a glance
- Drugs Camrelizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions
- Acronyms FOCUS-02
- 19 Sep 2024 Planned End Date changed from 1 Sep 2025 to 29 Mar 2026.
- 13 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 9 Sep 2023.
- 05 Nov 2022 Planned primary completion date changed from 9 Sep 2022 to 31 Dec 2022.